ERCC1作为非小细胞肺癌铂类获益预测指标 - Suppr

ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.

作者信息

Postel-Vinay Sophie, Soria Jean-Charles

机构信息

Sophie Postel-Vinay and Jean-Charles Soria, Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Paris-Saclay University, and INSERM, UMR981, Villejuif, France.

出版信息

J Clin Oncol. 2017 Feb;35(4):384-386. doi: 10.1200/JCO.2016.70.5053. Epub 2016 Nov 28.

DOI:10.1200/JCO.2016.70.5053

PMID:27893323

Abstract

摘要

相似文献

ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.

J Clin Oncol. 2017 Feb;35(4):384-386. doi: 10.1200/JCO.2016.70.5053. Epub 2016 Nov 28.

ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Cancer Invest. 2015 Apr;33(4):107-13. doi: 10.3109/07357907.2014.1001897. Epub 2015 Feb 3.

Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.

Anticancer Res. 2014 Jul;34(7):3707-13.

ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.

J Thorac Oncol. 2007 Oct;2(10):902-6. doi: 10.1097/JTO.0b013e318155a637.

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.

Lung Cancer. 2010 Oct;70(1):63-70. doi: 10.1016/j.lungcan.2010.05.010. Epub 2010 Jun 11.

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.

Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86. doi: 10.1007/s00280-014-2562-1. Epub 2014 Aug 9.

Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.

Lung Cancer. 2013 Nov;82(2):324-9. doi: 10.1016/j.lungcan.2013.08.001. Epub 2013 Aug 11.

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):17-24. doi: 10.1080/17425255.2018.1416095. Epub 2017 Dec 18.

Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.

Gene. 2013 Sep 10;526(2):265-74. doi: 10.1016/j.gene.2013.05.021. Epub 2013 May 30.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7.

引用本文的文献

Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.

ChemMedChem. 2024 Apr 16;19(8):e202300648. doi: 10.1002/cmdc.202300648. Epub 2024 Mar 5.

DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study.

Transl Lung Cancer Res. 2022 Dec;11(12):2539-2566. doi: 10.21037/tlcr-22-746.

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.

Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409.

Synergistic effects of olaparib combined with on the sensitivity of cisplatin in non-small cell lung cancer.

Oncol Lett. 2021 May;21(5):365. doi: 10.3892/ol.2021.12626. Epub 2021 Mar 10.

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.

Cancers (Basel). 2020 Aug 24;12(9):2398. doi: 10.3390/cancers12092398.

Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC).

DNA Repair (Amst). 2020 May;89:102837. doi: 10.1016/j.dnarep.2020.102837. Epub 2020 Mar 7.

Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.

Diagn Pathol. 2019 Sep 14;14(1):105. doi: 10.1186/s13000-019-0885-2.

AC138128.1 an Intronic lncRNA originating from ERCC1 Implies a Potential Application in Lung Cancer Treatment.

J Cancer. 2019 Jun 9;10(16):3608-3617. doi: 10.7150/jca.31832. eCollection 2019.

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8.

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Cancers (Basel). 2018 Mar 13;10(3):70. doi: 10.3390/cancers10030070.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献